News Releases Year None202220212020 Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements May 10, 2022 Tarsus to Present at Bank of America 2022 Healthcare Conference May 06, 2022 Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting May 05, 2022 Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock May 03, 2022 Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock May 02, 2022 Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year May 02, 2022 Tarsus to Host Webcast to Review Topline Results from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis Apr 29, 2022 Tarsus Presents Results of Two Studies Highlighting Demodex Blepharitis Patient Impact and Burden at the ASCRS 2022 Annual Meeting Apr 26, 2022 Tarsus Pharmaceuticals, Inc. Reports Full-Year 2021 Financial Results and Recent Business Achievements Mar 14, 2022 Tarsus to Present at Upcoming Investor Conferences Mar 09, 2022 Pagination Current page 1 Page 2 Next page next › Last page last » Presentations Tarsus Saturn-2 Phase 3 Trial Topline Results Presentation May 4, 2022 Tarsus Corporate Presentation May 4, 2022 Revolutionizing Treatment for Demodex Blepharitis Patients Webcast Presentation February 10, 2022